Breastfeeding and Jaundice
jaundice mgmt masthead

Supporting providers and parents in managing newborn jaundice

 

Request more information

We are always interested in engaging with you.

Let us know how we can help.

1
Select your area of interest
2
Contact details

The high percentage of newborns who develop jaundice combined with the move towards shorter stays in the maternity ward requires increasingly innovative ways to diagnose and manage this common condition to avoid readmission.

 

Left untreated, jaundice can lead to serious medical issues, including brain damage, so providers need clinically effective tools to help detect and treat it—with as little as possible discomfort to the infant and disruption to the mother and family.

 

We are committed to helping care providers deliver effective jaundice management and breastfeeding programs, while giving new parents the support they need throughout the critical first days of their infant’s life.

jaundice mgmt panel

Jaundice occurs in 60% of term and 80% pre-term infants. Hyperbilirubinemia is one of the leading causes of hospital readmissions.¹ ²

  Perspectives in jaundice management

jaundice mgmt article

A whole systems team approach to combat jaundice and encourage breastfeeding

 

An integrated hospital and community-based care program is helping new parents and newborns at risk for jaundice make positive strides to fight the condition.

 

Read on

jaundice mgmt article2

Unbound bilirubin – a predictor of kernicterus

 

Research findings on a novel relationship between skin bilirubin levels and free,unbound circulating bilirubin in the newborn baby.

 

Read on

Webinar: The role of transcutaneous bilirubinometry in neonatal jaundice management

Transcutaneous bilirubinometry (TcB) has the potential to change how hyperbilirubinemia is detected, and is covered in our 60 minute free webinar, recorded on July 26th, 2016.


Prof. De Luca, a key opinion leader in pediatrics and neonatal care, speaks about the causes of neonatal jaundice, and how to screen for it and treat it. He then discusses the relationships between free, unbound circulating bilirubin and skin bilirubin levels.

 

 

breast feeding video

         Speaker: Dr. Daniele De Luca, MD, PhD

         Associate Professor of Neonatology

         Chef de Service - Medical Director

         Pediatrics and Neonatal Critical Care

         APHP - South Paris University Hospitals,

         "A.Beclere" Medical Center, Paris, France

Transcutaneous bilirubin measurements in the assessment and management of neonatal jaundice

The American Academy of Pediatrics (AAP) has published guidelines for assessing newborns at risk for jaundice. The purpose of this white paper is to review the importance of early jaundice detection and critically examine the variability in current practice in order to promote the most safe, efficacious and cost-effective approach to care.

 

Download white paper

jaundice mgmt white paper grphic

Solutions for jaundice management

More in mother and child care

your passion our commitment

 

Specialty hub

 

Your passion, our commitment

 

Read more

Connecting with your tiniest patients

Topic

 

Connecting with your tiniest patients

 

Read more

1 Bhutani VK, Johnson L. A proposal to prevent severe neonatal hyperbilirubinemia and kernicterus. J Perinatol2009;29 Suppl 1:S61-S67.

2 Kumar RK. Neonatal jaundice. An update for family physicians. Aust Fam Physician 1999;28:679-682.

You are about to visit a Philips global content page

Continue

You are about to visit a Philips global content page

Continue

Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.

You are entering a Philips Healthcare Australia website
Please select the checkbox

The information on this site is not intended for consumers. The information is directed exclusively to health professionals, health practitioners, persons who are purchasing officers in hospitals, and persons who are engaged in the business of wholesaling therapeutic goods (as per s42AA of the Therapeutic Goods Act 1989 (Cth), and s6 of the Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021).

By clicking “Continue” you are indicating that you are one of the intended audiences. Click cancel to be redirected to the Philips website.